Mouse neuroblastoma adenylate cyclase. Adenosine and adenosine analogues as potent effectors of adenylate cyclase activity.
1. Intact mouse neuroblastoma NS20 cells, in the presence of cyclic adenosine 3':5'-monophosphate (cAMP) phosphodiesterase inhibitor, responded to adenosine (200 muM) and 2-chloroadenosine (200 muM) with a 20-fold increase in intracellular cAMP levels. AMP (200 muM) additions caused only a 3.5-fold cAMP level elevation. ATP, ADP, guanosine, cytidine, uridine, and guanine, all at 200 muM, had no effect on the cAMP level of these cells. 2. Homogenate NS20 adenylate cyclase activity was increased 2.5- to 4-fold by addition of 200 muM adenosine, 2-chloroadenosine, 2-hydroxyadenosine, or 8-methylaminoadenosine. Prostaglandin E1 additions (1.4 muM) produced about an 8-fold stimulation of homogenate cyclase activity. The Km of homogenate cyclase activation by adenosine and 2-chloroadenosine was 67.6 and 6.7 muM, respectively. Addition of 7-deazaadenosine, tolazoline, yohimbine, guanosine, cytosine, guanine, 2-deoxy-AMP, and adenine 9-beta-D-xylopyranoside, all at 200 muM were found to be without effect on homogenate NS20 adenylate cyclase. Two classes of inhibitors of homogenate NS20 adenylate cyclase activity were observed. One class, which included AMP, adenine, and theophylline, blocked 2-chloroadenosine but not prostaglandin E1 stimulation of cyclase. Theophylline was shown to be a competitive inhibitor of 2-chloroadenosine, with a Ki of 35 muM. The second class of inhibitors, which included 2'- and 5'-deoxyadenosine, inhibited unstimulated, 2-chloroadenosine and prostaglandin E1-stimulated homogenate cyclase activity to about the same degree. 3. Activation of NS20 homogenate adenylate cyclase by adenosine appears to be noncooperative. 4. The inhibitory action of putative "purinergic" neurotransmitters is postulated to be due to their effects on adenylate cyclase activity.
D000225:Adenine / Q000494:pharmacology; D000227:Adenine Nucleotides / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology*; D000249:Adenosine Monophosphate / Q000031:analogs & derivatives; D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D002999:Clone Cells; D003562:Cytidine / Q000494:pharmacology; D006147:Guanine / Q000494:pharmacology; D006151:Guanosine / Q000494:pharmacology; D007700:Kinetics; D051379:Mice; D009447:Neuroblastoma / Q000378:metabolism; D010761:Phosphorus Radioisotopes; D011458:Prostaglandins E / Q000494:pharmacology; D012266:Ribose / Q000031:analogs & derivatives; D013806:Theophylline / Q000494:pharmacology; D014043:Tolazoline / Q000494:pharmacology; D014529:Uridine / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
D000227:Adenine Nucleotides; D010761:Phosphorus Radioisotopes; D011458:Prostaglandins E; D006151:Guanosine; D015016:Yohimbine; D000249:Adenosine Monophosphate; D003562:Cytidine; D006147:Guanine; D012266:Ribose; D013806:Theophylline; D014043:Tolazoline; D000262:Adenylyl Cyclases; D000225:Adenine; D000241:Adenosine; D014529:Uridine